Insulet Co. (NASDAQ:PODD) Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. lessened its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 2.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 217,642 shares of the medical instruments supplier's stock after selling 6,400 shares during the quarter. Insulet comprises about 0.6% of Polar Asset Management Partners Inc.'s holdings, making the stock its 25th biggest holding. Polar Asset Management Partners Inc. owned about 0.31% of Insulet worth $56,820,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. SBI Securities Co. Ltd. acquired a new stake in Insulet in the fourth quarter valued at approximately $36,000. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of Insulet by 30.1% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier's stock valued at $2,192,000 after purchasing an additional 1,942 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Insulet by 21.8% in the 4th quarter. Jennison Associates LLC now owns 158,342 shares of the medical instruments supplier's stock valued at $41,338,000 after purchasing an additional 28,375 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of Insulet by 4.3% during the 4th quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier's stock worth $633,000 after purchasing an additional 100 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Insulet during the 4th quarter worth $9,822,000.

Analyst Ratings Changes

A number of research firms have weighed in on PODD. Citigroup restated a "buy" rating and issued a $380.00 price target (up from $320.00) on shares of Insulet in a research note on Thursday, May 22nd. Barclays upped their price objective on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Piper Sandler boosted their target price on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target on the stock in a research note on Tuesday, May 13th. Finally, Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $313.78.

Insulet Price Performance

NASDAQ PODD traded up $0.63 during trading hours on Friday, reaching $324.48. The company's stock had a trading volume of 261,523 shares, compared to its average volume of 708,245. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company's 50-day moving average is $275.57 and its two-hundred day moving average is $271.35. Insulet Co. has a fifty-two week low of $172.07 and a fifty-two week high of $329.33. The stock has a market cap of $22.84 billion, a PE ratio of 56.19, a PEG ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. During the same quarter in the prior year, the firm earned $0.73 earnings per share. The company's revenue for the quarter was up 28.8% compared to the same quarter last year. Analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.